Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 49.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 970 shares of the medical research company’s stock after buying an additional 320 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Amgen were worth $279,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Briaud Financial Planning Inc purchased a new stake in Amgen during the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. acquired a new position in Amgen in the fourth quarter valued at $29,000. Planned Solutions Inc. purchased a new position in Amgen during the fourth quarter worth about $30,000. Delos Wealth Advisors LLC boosted its stake in Amgen by 2,500.0% in the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the last quarter. Finally, Providence Capital Advisors LLC purchased a new stake in Amgen in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AMGN shares. Morgan Stanley raised their target price on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. UBS Group increased their target price on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Royal Bank of Canada cut their price objective on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. The Goldman Sachs Group boosted their target price on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and cut their price target for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $305.65.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.69% of the stock is owned by company insiders.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $314.85 on Wednesday. The business has a 50 day simple moving average of $282.91 and a 200-day simple moving average of $284.96. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a market capitalization of $168.89 billion, a price-to-earnings ratio of 44.98, a price-to-earnings-growth ratio of 2.83 and a beta of 0.60. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.98 earnings per share. As a group, equities research analysts expect that Amgen Inc. will post 19.46 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.